Dr Reddy's launches five generics in US
This article was originally published in Scrip
Dr Reddy's Laboratories launched five generic products in the US last month. These are levetiracetam tablets 250mg, 500mg, 750mg and 1000mg, generic versions of UCB's Keppra tablets; omeprazole capsules 40mg, a generic version of AstraZeneca's Prilosec DR; lamotrigine CD chewable tablets 5mg and 25mg and lamotrigine tablets 25mg, 100mg, 150mg and 200mg, generic versions of GlaxoSmithKline's Lamictal; and divalproex capsules and delayed-release pellets 125mg, a generic version of Abbott's Depakote delayed-release capsules. Dr Reddy's has 69 ANDAs, addressing innovator sales of $47 billion, pending at the US FDA.
You may also be interested in...
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.